0001104659-20-058217.txt : 20200507 0001104659-20-058217.hdr.sgml : 20200507 20200507180015 ACCESSION NUMBER: 0001104659-20-058217 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20200505 FILED AS OF DATE: 20200507 DATE AS OF CHANGE: 20200507 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Chan Phillip P. CENTRAL INDEX KEY: 0001442786 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-36792 FILM NUMBER: 20857975 MAIL ADDRESS: STREET 1: 1001 BRIGGS ROAD STREET 2: SUITE 280 CITY: MOUNT LAUREL STATE: NJ ZIP: 08054 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Cytosorbents Corp CENTRAL INDEX KEY: 0001175151 STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841] IRS NUMBER: 980373793 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 7 DEER PARK DRIVE, SUITE K CITY: MONMOUTH JUNCTION STATE: NJ ZIP: 08852 BUSINESS PHONE: 973-329-8885 MAIL ADDRESS: STREET 1: 7 DEER PARK DRIVE, SUITE K CITY: MONMOUTH JUNCTION STATE: NJ ZIP: 08852 FORMER COMPANY: FORMER CONFORMED NAME: MedaSorb Technologies CORP DATE OF NAME CHANGE: 20060807 FORMER COMPANY: FORMER CONFORMED NAME: GILDER ENTERPRISES INC DATE OF NAME CHANGE: 20020611 4 1 tm2019006d1_4.xml OWNERSHIP DOCUMENT X0306 4 2020-05-05 0 0001175151 Cytosorbents Corp CTSO 0001442786 Chan Phillip P. C/O CYTOSORBENTS CORPORATION 7 DEER PARK DRIVE, SUITE K MONMOUTH JUNCTION NJ 08852 1 1 0 0 Chief Executive Officer Common Stock 2020-05-05 4 M 0 14100 9.39 A 714682 D Stock Option (right to buy) 3.45 2020-05-05 4 M 0 14100 0 D 2030-05-05 Common Stock 14100 0 D Includes: (i) the following RSUs that will be settled into common stock, par value $0.0001 per share (the "Common Stock") upon vesting upon a "Change In Control" of CytoSorbents Corporation (the "Company") as defined in the Amended and Restated CytoSorbents Corporation 2014 Long-Term Incentive Plan: (a) 10,300 RSUs granted on March 15, 2018, (b) 18,700 RSUs granted on February 24, 2017, (c) 57,000 RSUs granted on June 7, 2016 and (d) 130,000 RSUs granted on April 8, 2015; (continue with footnote 2) (ii) the following RSUs (which vest as to one-third of the award on each of the date of grant, the first anniversary of the date of grant, and the second anniversary of the date of grant, subject to the reporting person's continued service as of the applicable vesting date) and will settle into Common Stock upon vesting: (a) 40,000 RSUs granted on February 28, 2020 and unvested on the date hereof, (b) 40,000 RSUs granted on July 22, 2019 and unvested on the date hereof, and (c) 1,834 RSUs granted on March 4, 2019 and unvested on the date hereof; and (iii) 416,848 shares of Common Stock owned by the reporting person. These stock options were originally granted on May 5, 2010 and became exercisable at the discretion of the Board of Directors of the Company based on criteria including (but not limited to) a timely completion of the sepsis trial, raising capital for the Company, and partnering and business development. /s/ Kathleen P. Bloch attorney-in-fact for Phillip P. Chan 2020-05-07